Skip to main content
For COVID-19 vaccine updates, please
review our information guide
and
sign up for Connect
. Continue your routine care with us by scheduling an
in-person appointment
or
Video Visit
.
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle menu options
Our Team
Patient Testimonials
News
For Patients
Toggle menu options
Health Information Library and Patient Resources
Support Groups and Helpful Links
Frequently Asked Questions
Your First Visit
Toggle menu options
Self-Referral
Lab Work/Procedures
Referring Physicians
Toggle menu options
Refer a Patient
Research and Clinical Trials
Toggle menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 9 results
Author
Title
Type
[
Year
]
Filters:
Author
is
Moreau, Philippe
[Clear All Filters]
2018
Goldschmidt H
,
Moreau P
,
Ludwig H
,
Niesvizky R
,
Chng W-J
,
Joshua D
,
Weisel K
,
Spencer A
,
Orlowski RZ
,
Feng S
et al.
. 2018.
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
.
Leuk Lymphoma. 59(6):1364-1374.
2017
Ludwig H
,
Dimopoulos MA
,
Moreau P
,
Chng W-J
,
Goldschmidt H
,
Hajek R
,
Facon T
,
Pour L
,
Niesvizky R
,
Oriol A
et al.
. 2017.
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
.
Leuk Lymphoma. 58(10):2501-2504.
Dimopoulos MA
,
A Stewart K
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel D
,
Mihaylov GG
,
Goranova-Marinova V
et al.
. 2017.
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
.
Br J Haematol. 177(3):404-413.
Dimopoulos MA
,
Goldschmidt H
,
Niesvizky R
,
Joshua D
,
Chng W-J
,
Oriol A
,
Orlowski RZ
,
Ludwig H
,
Facon T
,
Hajek R
et al.
. 2017.
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
.
Lancet Oncol. 18(10):1327-1337.
Castillo JJ
,
Jurczyszyn A
,
Brozova L
,
Crusoe E
,
Czepiel J
,
Davila J
,
Dispenzieri A
,
Eveillard M
,
Fiala MA
,
Ghobrial IM
et al.
. 2017.
IgM myeloma: A multicenter retrospective study of 134 patients.
.
Am J Hematol. 92(8):746-751.
2016
Avet-Loiseau H
,
Fonseca R
,
Siegel D
,
Dimopoulos MA
,
Spicka I
,
Masszi T
,
Hajek R
,
Rosiñol L
,
Goranova-Marinova V
,
Mihaylov G
et al.
. 2016.
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
.
Blood. 128(9):1174-80.
A Stewart K
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Niesvizky R
,
Jakubowiak AJ
et al.
. 2016.
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
.
J Clin Oncol. 34(32):3921-3930.
2015
A Stewart K
,
S Rajkumar V
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Mihaylov GG
et al.
. 2015.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
.
N Engl J Med. 372(2):142-52.
2014
Palumbo A
,
S Rajkumar V
,
San Miguel JF
,
Larocca A
,
Niesvizky R
,
Morgan G
,
Landgren O
,
Hajek R
,
Einsele H
,
Anderson KC
et al.
. 2014.
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
.
J Clin Oncol. 32(6):587-600.